Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis.

Authors

Roy Khalaf, Alexandre Ton That, Natacha Tardio, Waqqas Afif, Rilla Schneider, Moshe Ben-Shoshan

Published in

International archives of allergy and immunology. Pages 1-11. Jul 15, 2026. Epub Jul 15, 2026.

Abstract

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disorder of the esophagus driven by type-2 inflammation. Dupilumab, a monoclonal antibody targeting the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes , has recently emerged as a targeted biologic therapy for EoE. This systematic review evaluates the evidence for dupilumab in EoE across pediatric and adult populations, focusing on efficacy, safety, and symptom improvement.
MEDLINE and Embase were searched from inception to June 30, 2025. Eligible studies included randomized controlled trials, cohort studies, case-control studies, and case reports reporting dupilumab use in confirmed EoE. Study screening and quality assessment were performed in duplicate. . Data on demographics, atopic comorbidities, dosing regimens, histologic outcomes, symptom improvement, and adverse events were extracted and summarized descriptively.
Nineteen studies (three randomized trials, nine cohorts, seven case reports) comprising 760 patients were included. Dupilumab was most commonly initiated following inadequate response or intolerance to proton pump inhibitors, swallowed corticosteroids, or dietary therapy. Across RCTs, histologic remission (≤15 eos/hpf) occurred in 60%-84% of dupilumab-treated patients versus <10% of placebo. Cohort studies demonstrated comparable rates (68%-93%), with pediatric cohorts showing particularly robust responses (up to 90% remission). Meta-analysis using a random-effects logit model demonstrated a pooled histologic remission rate of 75.5% (95% CI, 67.4-82.1%) and a symptom improvement rate of 84.1% (95% CI, 77.8-88.9%).
Dupilumab represents a promising therapeutic option, particularly for patients with inadequate response to PPI therapy, including those unable to maintain dietary restrictions. Future research should focus on predictors of response, durability of remission beyond one year, and comparative effectiveness relative to other therapies.

PMID:
42455743
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.